Safety of bilateral intravitreal injections delivered in a teaching institution

Daniel L. Chao, Ninel Gregori, Joyce Khandji, Raquel Goldhardt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.

Original languageEnglish
Pages (from-to)991-993
Number of pages3
JournalExpert Opinion on Drug Delivery
Volume11
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

Intravitreal Injections
Teaching
Veterans Hospitals
Safety
Endophthalmitis
Disease Outbreaks
Patient Care
Physicians
Injections
Therapeutics

Keywords

  • Aflibercept
  • Anti-VEGF
  • Bevacizumab
  • Bilateral intravitreal injection
  • Ophthalmology resident
  • Ranibizumab
  • Teaching institution
  • Veterans Affairs hospital

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Safety of bilateral intravitreal injections delivered in a teaching institution. / Chao, Daniel L.; Gregori, Ninel; Khandji, Joyce; Goldhardt, Raquel.

In: Expert Opinion on Drug Delivery, Vol. 11, No. 7, 01.01.2014, p. 991-993.

Research output: Contribution to journalArticle

@article{e3bb8c064125494f8408a71edf39f77a,
title = "Safety of bilateral intravitreal injections delivered in a teaching institution",
abstract = "Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.",
keywords = "Aflibercept, Anti-VEGF, Bevacizumab, Bilateral intravitreal injection, Ophthalmology resident, Ranibizumab, Teaching institution, Veterans Affairs hospital",
author = "Chao, {Daniel L.} and Ninel Gregori and Joyce Khandji and Raquel Goldhardt",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/17425247.2014.909806",
language = "English",
volume = "11",
pages = "991--993",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Safety of bilateral intravitreal injections delivered in a teaching institution

AU - Chao, Daniel L.

AU - Gregori, Ninel

AU - Khandji, Joyce

AU - Goldhardt, Raquel

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.

AB - Intravitreal injection is one of the most common in-office procedures performed in ophthalmic practices. In teaching institutions such as the Veterans Affairs (VA) Hospitals, patient care is delivered by physicians-in-training, while mastering intravitreal injection technique. Infectious endophthalmitis and visual loss are the most feared complications of intravitreal injections, especially in the context of recent outbreaks caused by contaminated compounded medications. Ophthalmologists and ophthalmic educators increasingly face the dilemma of timing as well as balancing the risks and benefits of bilateral treatments required by many patients. In this editorial, we discuss published reports of bilateral injections, summarize our experience with bilateral intravitreal injections in a teaching setting at the Miami VA Hospital and list our recommendations for minimizing the risk of infectious endophthalmitis.

KW - Aflibercept

KW - Anti-VEGF

KW - Bevacizumab

KW - Bilateral intravitreal injection

KW - Ophthalmology resident

KW - Ranibizumab

KW - Teaching institution

KW - Veterans Affairs hospital

UR - http://www.scopus.com/inward/record.url?scp=84903220999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903220999&partnerID=8YFLogxK

U2 - 10.1517/17425247.2014.909806

DO - 10.1517/17425247.2014.909806

M3 - Article

C2 - 24815986

AN - SCOPUS:84903220999

VL - 11

SP - 991

EP - 993

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 7

ER -